Are you interested in getting involved in research to further our understanding of celiac disease? See below for information about opportunities to become a participant in research studies.
POWER-C (Promotion of Optimal Well-Being, Education and Regulation for Celiac Disease)
The University of Calgary has a FREE brand new, online, evidence-based program for people newly diagnosed and/or struggling with celiac disease. All North American adults diagnosed with celiac disease (blood test and/or biopsy) are eligible to participate. You do not have to follow a strict gluten-free diet to participate.
The purpose of this study is to examine the impact of a four-week program (spread out over eight weeks) for adults who are newly diagnosed and/or struggling with celiac disease. After completing the program and questionnaires, participants will be entered into a drawing to win one of eight $25 Amazon gift cards.
POWER-C contains four modules to be completed bi-weekly over the course of eight weeks, and each module will take you approximately 25 minutes to complete. The content of the modules depends on which group you are randomized to, however, in general the program involves education on celiac disease/gluten-free diet and evidence-based strategies to help you cope with celiac disease as someone newly diagnosed and/or struggling. Please note that the content is specifically for people who are newly diagnosed and/or struggling with celiac disease.
For more information, please email firstname.lastname@example.org
Celimmune, in partnership with the University of Chicago Celiac Disease Center, and Celiac Disease Foundation have joined forces to deploy the iCureCeliac® patient registry as a screen for phase 2 clinical study for refractory celiac disease type II. This is the first-ever use of the new and growing iCureCeliac® registry to support celiac disease therapeutic treatment development.
Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing immune-mediated diseases, has commenced screening patients in its Phase 2 clinical study for AMG 714, an investigational anti-IL-15 monoclonal antibody for the treatment of refractory celiac disease Type II (RCD-II). The randomized, double-blind, parallel-group study is expected to enroll 24 patients with a confirmed diagnosis of RCD-II. Study duration is 20 weeks and visits to the site take place every two weeks to receive intravenous infusion of AMG 714 or placebo. Intestinal biopsies will be taken before and after treatment to evaluate the efficacy of AMG 714. Patients enrolled will maintain a strict gluten-free diet during the study.
To see if you qualify to participate in the study, please contact email@example.com.
The University of Chicago Celiac Disease Center is currently conducting a research study for teenagers with celiac disease and their parents, to better understand the feelings and coping skills of adolescent patients with celiac disease and how this affects their adherence to a gluten-free diet later in life. The primary goal is to use this information to improve adherence to a gluten-free diet for these patients as they get older. If your child is between the ages of 12 and 18 and is a celiac disease patient at The University of Chicago Medical Center, he or she may qualify.
Parents should contact Celiac Center Research Coordinator, Diane McKiernan, by phone at 773-702-3572 or by e-mail at firstname.lastname@example.org for more information.
The University of Chicago Celiac Disease Center is enrolling patients for a clinical study testing the effectiveness of a pill for celiac disease. Montelukast is a drug that is FDA-approved for the treatment of asthma and is being tested for the treatment of celiac disease. The study is taking place at the University of Chicago Celiac Disease Center. In order to be eligible for the study you must:
- Have celiac disease
- Be 18 years of age or older
- Have been on a gluten-free diet for at least one year
- Be willing to eat bread containing gluten
If enrolled, you will be given the drug or a placebo and be asked to:
- Travel to the Chicagoland area for six study visits over a three month period
- Have multiple blood draws, endoscopy with biopsy and brushings, and provide stool samples
- Answer some questions regarding your health
If you are interested, please contact Meaghan Peterson at 773-702-9743 or email@example.com